

**Pegfilgrastim (Neulasta<sup>®</sup>)**  
**Amgen Ltd**

**No. 67/03**

## Summary of Recommendation

13 October, 2003

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

### **ADVICE**

Recommended for restricted use within NHS Scotland.

### **REASONS FOR ADVICE**

This sustained release formulation of filgrastim can be used for reducing the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy within the context of current practice guidelines.

Pegfilgrastim is a pegylated form of colony stimulating factor (CSF), with a sustained duration of action allowing administration once per chemotherapy cycle. It has benefits of convenience for patients and staff.

Professor D H Lawson  
Chairman